Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02553395 · ClinicalTrials.gov registry record · NA

One Week Assessment of The Phenacite Lens

A NA study, sponsored by CooperVision.

Completed
Registry status
NA
Development phase
30
Enrollment target

NCT02553395: Completed NA study, sponsored by CooperVision.

NCT02553395 is a NA study that has completed, run by CooperVision. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02553395, a NA study, has completed, sponsored by CooperVision.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target

Study Summary

This study will investigate performance criteria over one week of daily wear to determine if the Study Test contact lens performs equivalently to the comfilcon A contact lenses in terms of subjective ratings and of visual performance. The study test lens was not the final optical design and the study results were not used for the design validation.

Primary Outcome

Binocular Distance visual acuity High Illumination High Contrast was assessed using logMAR (0.02 logMAR= 1 letter)

Interventions

  • DEVICE Phenacite (Test) contact lens
  • DEVICE comfilcon A contact lens

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2015-09
Est. Completion 2015-10
Phase NA
CooperVision

64 total trials

What the finished NCT02553395 record still lists

NCT02553395 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which Phenacite (Test) contact lens is the first listed.

NCT02553395 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02553395 about?

NCT02553395 is a clinical study titled "One Week Assessment of The Phenacite Lens". This study will investigate performance criteria over one week of daily wear to determine if the Study Test contact lens performs equivalently to the comfilcon A contact lenses in terms of subjective ratings and of visual performance. The study test lens was not the final optical design and the stu...

What is the current status of trial NCT02553395?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2015-09. Estimated completion is 2015-10.

What interventions are being tested in trial NCT02553395?

The interventions under investigation include: Phenacite (Test) contact lens (DEVICE), comfilcon A contact lens (DEVICE).

Who is sponsoring clinical trial NCT02553395?

This trial is sponsored by CooperVision, which has 64 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02553395's enrollment target sits among peer trials

30 1593rd of 2000 higher than 299 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02553395, the US trial registry maintained by the National Library of Medicine. NCT02553395 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.